Allergan to divest rights to Brazikumab and Zenpep
Irish pharmaceutical company Allergan has agreed to divest its rights to brazikumab (IL-23 inhibitor) to AstraZeneca and gastrointestinal medication Zenpep to Nestle. The divesture is aimed at complementing